Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

BenevolentAI: Notice of Preliminary Results

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary results for the year ended 31 December 2023 on Thursday, 14 March 2024.

Management will host an in-person analyst briefing at 13:00 GMT (08:00 ET) on the day of the results at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom). To register your interest in attending either in person or virtually, analysts should contact FTI Consulting at [email protected].

A recording of the webcast will be made available in the investor section of the Company's website shortly afterwards.

About BenevolentAI

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Category: Non-regulatory

These press releases may also interest you

at 09:05
QuantHealth, an AI-powered clinical trial design company, today announced the formation of its inaugural Advisory Board. Founding members Michel Vounatsos, former CEO of Biogen, Rob Scott, former Chief Medical Officer for AbbVie, and Christian Hein,...

at 09:05
ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a leading global biotechnology company selected ValGenesis iRisk to digitalize the quality risk management processes across its...

at 09:03
Vero AI, a first-of-its-kind analytical engine and scoreboard that helps enterprises fully harness the potential of advanced technology including artificial intelligence while minimizing risk, announced the findings of its inaugural "Generating...

at 09:00
ROYAL CANIN® U.S., a division of Mars, Incorporated and leader in pet health nutrition, has announced an expansion to its Veterinary Gastrointestinal (GI) portfolio. Gastrointestinal issues are the 3rd and 4th most common issue in cats and dogs that...

at 09:00
Peoplehood, a first-of-its-kind social wellness company created by the founders of SoulCycle, today announced the launch of Peoplehood @Work. The @Work program consists of a series of facilitated, interactive team conversations, customized for each...

at 09:00
Addressing cultural friction within operating rooms has emerged as a critical imperative for healthcare institutions nationwide. Surgical Directions sheds light on the detrimental effects of cultural discord, including high clinician and staff...

News published on and distributed by: